Glenmark Pharmaceuticals to investigate GBR 1342 in Phase I trial for multiple myeloma

Indian pharmaceutical firm Glenmark Pharmaceuticals has obtained clearance from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application to commence a Phase I clinical trial of GBR 1342 to treat patients with multi …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news